Abigail Alliance Looks For Paths Forward After Court Blocks Drug Access Suit
Executive Summary
After losing at the appeals court in its bid to overturn FDA's regulations on access to experimental therapies, the Abigail Alliance is considering several legal options. The group is preparing to ask the Supreme Court to consider the case, but if that bid fails, alternatives include congressional action and bringing another case in a different jurisdiction
You may also be interested in...
ACCESS Act back in House (and Senate)
Sen. Sam Brownback, R-Kan., and Rep. Diane Watson, D-Calif., re-introduced the Access, Compassion, Care and Ethics for Seriously Ill Patients Act (ACCESS) May 21. The bill, initially introduced in 2005, would expand investigational treatment access for terminally ill patients who have exhausted other medical options (1"The Pink Sheet," Aug. 27, 2007, p. 9)
ACCESS Act back in House (and Senate)
Sen. Sam Brownback, R-Kan., and Rep. Diane Watson, D-Calif., re-introduced the Access, Compassion, Care and Ethics for Seriously Ill Patients Act (ACCESS) May 21. The bill, initially introduced in 2005, would expand investigational treatment access for terminally ill patients who have exhausted other medical options (1"The Pink Sheet," Aug. 27, 2007, p. 9)
FDA’s Office of Chief Counsel Is Growing Its Ranks As It Amends Its Act
Tucked away on the sixth floor of the Parklawn Building in Rockville, FDA's Office of Chief Counsel is calm and quiet. Beneath the surface, however, there is a surge of activity. One of the main engines driving the agency, the 80-lawyer shop helps craft regulations, manages dozens of lawsuits and oversees every enforcement action